c-Met receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Nail clubbing, also known as digital clubbing or clubbing, is a deformity of the finger or toe nails associated with several diseases, anomalies and defects, some congenital, mostly of the heart and lungs. When it occurs together with joint effusions, joint pains, and abnormal skin and bone growth it is known as hypertrophic osteoarthropathy. Clubbing is associated with lung cancer, lung infections, interstitial lung disease, cystic fibrosis, or cardiovascular disease. Clubbing may also run in families, and occur unassociated with other medical problems. Clubbing has been recognized as a sign of disease since the time of Hippocrates. It is seen in 1% of internal medicine admissions and is associated with serious underlying disease in 40% of these admissions.
=== Pharmacokinetics === A 2007 human pharmacokinetic study of sodium RLA demonstrated the maximum concentration in plasma and bioavailability are significantly greater than the free acid form, and rivals plasma levels achieved by intravenous administration of the free acid form. Additionally, high plasma levels comparable to those in animal models where Nrf2 was activated were achieved. The various forms of LA are not bioequivalent. Very few studies compare individual enantiomers with racemic lipoic acid. It is unclear if twice as much racemic lipoic acid can replace RLA. The toxic dose of LA in cats is much lower than that in humans or dogs and produces hepatocellular toxicity.
== Miscellaneous == John Parke Custis* (1777), stepson of George Washington Philip Hamilton (1800), eldest son of Alexander Hamilton and Elizabeth Schuyler Hamilton David Augustus Clarkson (1810), landowner and grandson-in-law of Robert R. Livingston James Lenox (1818), bibliophile, founder of the Lenox Library, later incorporated into the New York Public Library; also founder of the Presbyterian Hospital John Lloyd Stephens (1822), explorer, archaeologist, special ambassador to Central America, and president of the Panama Railroad William R. Travers (1838), founder of the Travers Stakes William H. Herriman (1849), expatriate American art collector Cornelius Jeremiah Vanderbilt* (1850), son of Cornelius Vanderbilt Augustus Newbold Morris (1860), socialite and former president of The Metropolitan Club Winthrop Rutherfurd (1884), socialite known for his romance with Consuelo Vanderbilt and marriage to Lucy Mercer Rutherfurd, mistress of Franklin D. Roosevelt Gavin Arthur (1922), San Francisco astrologer and sexologist; grandson of U.S. President Chester A. Arthur Oswald Jacoby (1922), bridge player Fred Glazer (1958), librarian and director of the West Virginia Library Commission Arthur MacArthur IV (1960), son of General of the Army Douglas MacArthur Ashrita Furman (1976), holder of the most Guinness Book of World Records records Daniel Kottke (1977), college friend of Steve Jobs and 12th employee of Apple Inc. Sergey Kudrin (1981), chess grandmaster and three-time winner of the U.S.
Sources: en.wikipedia.org
=== Mechanism of action === Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses stomach acid secretion by specific inhibition of the H+/K+-ATPase system found at the secretory surface of gastric parietal cells. Because this enzyme system is regarded as the acid (proton, or H+) pump within the gastric mucosa, omeprazole inhibits the final step of acid production. Omeprazole also inhibits both basal and stimulated acid secretion irrespective of the stimulus as it blocks the last step in acid secretion. The drug binds non-competitively so it has a dose-dependent effect. The inhibitory effect of omeprazole occurs within one hour after oral administration. The maximum effect occurs within two hours. The duration of inhibition is up to 72 hours. When omeprazole is stopped, baseline stomach acid secretory activity returns after three to five days. The inhibitory effect of omeprazole on acid secretion will plateau after four days of repeated daily dosing. Omeprazole is only effective on active H+/K+-ATPase pumps. These pumps are stimulated in the presence of food to aid in digestion.
Stella Maris, the newly elected rector of St Andrews University, faces calls from students to apologise or resign after she said in an email that Palestinians had suffered "apartheid, siege, illegal occupation and collective punishment" during the Israel-Gaza war. 28 November – The Scottish Government publish a consultation for a new heating bill that will see the phasing out of gas boilers in Scotland, but the original start date of 2025 is expected to be delayed by three years.
Additionally, models accounting for the simultaneous effect of pH, micelle and organic concentration have been suggested. These models allow for further enhancement of the optimization of the separation of weak acids and bases. One research group, Rukhadze, et al. derived a first order linear relationship describing the influence of micelle and organic concentration, and pH on the selectivity and resolution of seven barbiturates. The researchers discovered that a second order mathematical equation would more precisely fit the data. The derivations and experimental details are beyond the scope of this discussion. The model was successful in predicting the experimental conditions necessary to achieve a separation for compounds which are traditionally difficult to resolve. Jandera, Fischer, and Effenberger approached the modeling problem in yet another way. The model used was based on lipophilicity and polarity indices of solutes. The lipophilicity index relates a given solute to a hypothetical number of carbon atoms in an alkyl chain. It is based and depends on a given calibration series determined experimentally. The lipophilicity index should be independent of the stationary phase and organic modifier concentration. The polarity index is a measure of the polarity of the solute-solvent interactions. It depends strongly on the organic solvent, and somewhat on the polar groups present in the stationary phase. 23 compounds were analyzed with varying mobile phases and compared to the lipophilicity and polarity indices.
The Japanese Hisatugu Numata developed the first panoramic radiograph in 1933/34. This was followed by the development of intraoral panoramic X-ray units, in which the X-ray tube is placed intraorally (inside the mouth) and the X-ray film extraorally (outside the mouth). At the same time, Horst Beger from Dresden in 1943 and the Swiss dentist Walter Ott in 1946 worked on the Panoramix (Koch & Sterzel), Status X (Siemens) and Oralix (Philips). Intraoral panoramic devices were discontinued at the end of the 1980s because the radiation exposure was too high in direct contact with the tongue and oral mucosa due to the intraoral tube.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.